MedWatch

Argenx wants to keep main asset to itself

Last year, Argenx became Danish Leo Pharma's first biotech partner, but the Belgian company's strategy is actually focused on avoiding partnerships as much as possible.

Foto: Colourbox

In 2017, the alliance with Belgian biotech firm Argenx marked Leo Pharma's first encounter with biological therapies, and since then the Danish dermatology group has continued on this path.

But actually, the collaboration with Leo Pharma is an exception to the rule for Argenx that usually aims to keep partners away from the company's drugs. At least, when it comes to the main asset efgartigimod.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier